Accuracy of Coplanar Template Assisted Seed Implantation for Abdominal and Pelvic Cancer

Last updated: June 14, 2024
Sponsor: Peking University Third Hospital
Overall Status: Active - Recruiting

Phase

N/A

Condition

Pelvic Cancer

Treatment

N/A

Clinical Study ID

NCT05483452
ChiECRCT20220009
  • Ages 18-85
  • All Genders

Study Summary

In recent years, template guidance has been applied and developed in the field of puncture related operations, such as template-assisted radioactive seed implantation. With the guidance of template, needle pathway of seed implantation, biopsy and fiducial marker implantation can be precisely planned actual operation, which is conducive to the accurate proceeding. Templates can be divided into coplanar templates and non-coplanar templates. The digital coplanar template coordinate puncture system has been developed in China and has been applied in clinical practice.

In previous studies, coplanar template assisted CT-guided radioactive seed implantation has good clinical feasibility for head and neck cancer. However, the accuracy of Coplanar Template Assisted Seed Implantation for Abdominal and Pelvic cancer are lacking in prospective studies. The study aims to prospectively observe the accuracy and safety of Coplanar Template Assisted Seed Implantation for Abdominal and Pelvic cancer.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. Ages 18 to 85

  2. Single or multiple abdominal or pelvic tumors (solid, partially solid)

  3. Without taking drugs affecting coagulation and/or platelet aggregation are used; Ifused, the drug has been discontinued for a sufficient period of time (e.g. 1 week)

  4. KPS>60 points with expected survival >3 months, no serious or uncontrolledunderlying diseases, clinical evaluation patients can tolerate puncture

  5. Planned seed implantation with applicable puncture path

  6. With informed consent.

Exclusion

Exclusion Criteria:

  1. Poor organ function (e.g. Liver decompensation)

  2. The lesion close to blood vessels and intestine, or there is portal veinhypertension and superior vena cava compression, etc., which are expected to havehigh risks of puncture bleeding and intestinal injury

  3. Poor compliance, unable to complete coordination

  4. Paticipant who is considered inappropriate or unwilling to participate in thisclinical trial for other reasons.

Study Design

Total Participants: 34
Study Start date:
March 01, 2024
Estimated Completion Date:
March 31, 2025

Connect with a study center

  • Peking University Third Hospital

    Beijing, Beijing
    China

    Active - Recruiting

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.